Sanofi reported strong financial results for 2022, with company sales growing 7.0% to €42,997 million and business EPS increasing 17.1% to €8.26. The company will continue investing in science as it launches the next phase of its strategy to maintain progress developing first and best in class medicines. Recent regulatory approvals in Europe include treatments for prurigo nodularis, a COVID-19 booster vaccine, prevention of respiratory syncytial virus in infants, and cold agglutinin disease.